Camurus is committed to developing and commercializing innovative and long-acting medicines for the treatment of severe and chronic conditions, including opioid dependence, pain, cancer and endocrine disorders. New drug products are based on our proprietary FluidCrystal® drug delivery technologies with the purpose to deliver improved quality of life, treatment outcomes and resource utilization. The company’s share is listed on Nasdaq Stockholm under the ticker “CAMX”.
The cornerstones of there operations are innovation and efficient development of therapeutics with the potential to significantly improve the treatment and quality of life of patients with severe and chronic diseases. There progress is accomplished thanks to our skilled, professional and dedicated teams and our unique technologies.